Laura Chico
Stock Analyst at Wedbush
(4.05)
# 580
Out of 4,650 analysts
199
Total ratings
48.12%
Success rate
12.33%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Downgrades: Neutral | $29 → $4 | $4.01 | -0.25% | 3 | Oct 23, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $9 → $8 | $8.48 | -5.66% | 8 | Oct 9, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $17 → $25 | $18.37 | +36.09% | 9 | Oct 9, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $22 | $7.78 | +182.78% | 1 | Oct 3, 2024 | |
| BIIB Biogen | Maintains: Neutral | $210 → $205 | $183.47 | +11.73% | 16 | Sep 23, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Outperform | $40 → $44 | $59.57 | -26.14% | 7 | Sep 17, 2024 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $31 | $34.45 | -10.01% | 8 | Aug 16, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Neutral | $40 → $48 | $71.03 | -32.42% | 6 | Aug 14, 2024 | |
| ATXS Astria Therapeutics | Reiterates: Outperform | $22 | $11.99 | +83.49% | 8 | Aug 13, 2024 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $0.91 | +337.49% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $41 | $27.41 | +49.58% | 13 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $41.78 | +17.28% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $27.75 | +29.73% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $7.07 | -0.99% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $27.47 | -5.35% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $43 → $46 | $52.80 | -12.88% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $6.01 | +83.03% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $7.28 | +174.73% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $22.74 | +84.70% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $3.82 | +502.09% | 7 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $12.40 | +37.10% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.26 | +1,714.16% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $116.19 | +30.82% | 7 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $23.75 | +30.53% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $1.02 | +978.43% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $1.19 | +572.27% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $34 | $42.97 | -20.88% | 6 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $5.41 | -7.58% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $69.91 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.88 | +165.96% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $50.95 | +191.46% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $16.20 | +4,344.44% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $13.39 | +1,991.11% | 1 | Apr 21, 2017 |
Alto Neuroscience
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $4.01
Upside: -0.25%
Sage Therapeutics
Oct 9, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $8.48
Upside: -5.66%
Travere Therapeutics
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $18.37
Upside: +36.09%
Larimar Therapeutics
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $7.78
Upside: +182.78%
Biogen
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $183.47
Upside: +11.73%
Longboard Pharmaceuticals
Sep 17, 2024
Maintains: Outperform
Price Target: $40 → $44
Current: $59.57
Upside: -26.14%
Edgewise Therapeutics
Aug 16, 2024
Reiterates: Outperform
Price Target: $31
Current: $34.45
Upside: -10.01%
Praxis Precision Medicines
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $71.03
Upside: -32.42%
Astria Therapeutics
Aug 13, 2024
Reiterates: Outperform
Price Target: $22
Current: $11.99
Upside: +83.49%
Gossamer Bio
Aug 13, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.91
Upside: +337.49%
Aug 9, 2024
Maintains: Neutral
Price Target: $38 → $41
Current: $27.41
Upside: +49.58%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $41.78
Upside: +17.28%
Aug 9, 2024
Maintains: Outperform
Price Target: $38 → $36
Current: $27.75
Upside: +29.73%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $7.07
Upside: -0.99%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $27.47
Upside: -5.35%
Aug 2, 2024
Maintains: Neutral
Price Target: $43 → $46
Current: $52.80
Upside: -12.88%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $6.01
Upside: +83.03%
Jul 31, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.28
Upside: +174.73%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $22.74
Upside: +84.70%
Jul 11, 2024
Reiterates: Outperform
Price Target: $23
Current: $3.82
Upside: +502.09%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $12.40
Upside: +37.10%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.26
Upside: +1,714.16%
May 29, 2024
Reiterates: Outperform
Price Target: $152
Current: $116.19
Upside: +30.82%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $23.75
Upside: +30.53%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $1.02
Upside: +978.43%
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $1.19
Upside: +572.27%
Mar 21, 2024
Maintains: Neutral
Price Target: $21 → $34
Current: $42.97
Upside: -20.88%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $5.41
Upside: -7.58%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $69.91
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.88
Upside: +165.96%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $50.95
Upside: +191.46%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $16.20
Upside: +4,344.44%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $13.39
Upside: +1,991.11%